Browsing by Author Liaw, S

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 3 to 7 of 7 < previous 
TitleAuthor(s)Issue DateViews
 
Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients
Proceeding/Conference:Journal of Hepatology
Ma, XLLalezari, JNguyuen, TBae, HoSchiff, ERFung, SYuen, RMFHassanein, THann, HWElkhashab, MDieterich, DSulkowski, MKwo, PNahass, RAgarwal, KRamji, APark, JRavendhran, NChan, SWeilert, FHan, SHAyoub, WGane, EJacobson, IBennett, MHuang, QYan, RHuey, VRuby, ELiaw, SColonno, RLopatin, U
2019
74
 
Interim safety, tolerability pharmacokinetics, and antiviral activity of ABI-H0731, a novel core protein allosteric modulator, in healthy volunteers and non-cirrhotic viremic subjects with chronic hepatitis B
Proceeding/Conference:Journal of Hepatology
Yuen, RMFAgarwal, KGane, ESchwabe, CCheng, WSievert, WKim, DJAhn, SHLim, YSVisvanathan, KRuby, ELiaw, SColonno, RLopatin, U
2018
110
 
NVR 3-778, a first-in-class HBVCORE inhibitor, alone and incombination with Peg-interferon (PEGIFN), in treatment naive HBeAg-Positive patients: early reductions in HBV DNA and HBeAg
Proceeding/Conference:Journal of Hepatology
Yuen, RMFKim, DJWeilert, FChan, HLYLalezari, JPHwang, SGNguyen, TLiaw, SBrown, NKlumpp, KFlores, OHartman, GGane, E
2016
130
 
Pharmacokinetics (PK) and PK modeling of the first-in- class HBV core inhibitor NVR 3-778 dosed once- (QD) or twice daily (BD) in healthy volunteers (HVs) and HBeAg-positive patients witn chronic HBV infection (CHBV)
Proceeding/Conference:Hepatology
Kakuda, TDel Bene, EYuen, RMFGane, EJKim, SLiaw, SBrown, NKlumpp, KFlores, FChanda, S
2016
74
 
Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial
Journal:The Lancet Gastroenterology & Hepatology
Yuen, MFAgarwal, KGane, EJSchwabe, CAhn, SHKim, DJLim, YSCheng, WSievert, WVisvanathan, KRuby, ELiaw, SYan, RHuang, QColonno, RLopatin, U
2020
31
Showing results 3 to 7 of 7 < previous